TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 200nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: <300nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 400nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 600nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 600nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 600nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 700nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 700nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 800nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 800nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 800nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 800nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 800nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 900nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.30E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.60E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataIC50: 1.60E+3nMAssay Description:To a cultured CHO cell strain which stably expresses hERG was added each test compound to adjust the final concentration of DMSO to 0.0135 to 0.5%. T...More data for this Ligand-Target Pair